Supernus says ADHD drug trounces rivals, but shares slideSupernus Pharma has two phase III trials showing its attention-deficit hyperactivity disorder (ADHD) drug SPN-812 met its objectives, Share XSupernus says ADHD drug trounces rivals, but shares slidehttps://pharmaphorum.com/news/supernus-says-adhd-drug-trounces-rivals-but-shares-slide/
pharmaphorum welcomes George Underwood to its editorial helmWith its focus always on top quality, engaging editorial content, pharmaphorum is pleased to announce that George Underwood Share Xpharmaphorum welcomes George Underwood to its editorial helmhttps://pharmaphorum.com/news/pharmaphorum-welcomes-george-underwood-to-its-editorial-helm/
Lucid Group makes four new medical writing additionsLucid has appointed four new starters to its medical writing teams across its UK and US operations. Sonal Share XLucid Group makes four new medical writing additionshttps://pharmaphorum.com/news/lucid-group-medical-writing-team/
Nearly 300 gene and cell therapies in development – reportPharma is becoming increasingly focused on gene and cell therapies, with nearly 300 in clinical development or awaiting Share XNearly 300 gene and cell therapies in development – reporthttps://pharmaphorum.com/news/nearly-300-gene-and-cell-therapies-in-development-report/
AbbVie suffers fresh setback with lung cancer drug Rova-TAbbVie has suffered a further setback with its oncology drug Rova-T, after early data from a lung cancer Share XAbbVie suffers fresh setback with lung cancer drug Rova-Thttps://pharmaphorum.com/news/abbvie-suffers-fresh-setback-with-lung-cancer-drug-rova-t/
New AI tech could outperform humans in medical imagingTech firm Cambridge Consultants has announced a new Artificial Intelligence (AI) technology that can produce more accurate medical Share XNew AI tech could outperform humans in medical imaginghttps://pharmaphorum.com/news/new-ai-tech-could-outperform-humans-in-medical-imaging/
Shareholders approve Takeda’s $59bn takeover of ShireTakeda’s $59 billion acquisition of Shire has been backed by shareholders from both companies, clearing the way for Share XShareholders approve Takeda’s $59bn takeover of Shirehttps://pharmaphorum.com/news/shareholders-approve-takedas-59bn-takeover-of-shire/
After delayed IPO, Mereo gets US listing via OncoMed mergerUK biotech Mereo BioPharma is merging with Californian biotech OncoMed in an all-stock deal that swells its pipeline Share XAfter delayed IPO, Mereo gets US listing via OncoMed mergerhttps://pharmaphorum.com/news/after-delayed-ipo-mereo-gets-us-listing-via-oncomed-merger/
Digital health market to top $379bn by 2024The digital health market is set to exceed $379 billion by 2024, according to a new report by Share XDigital health market to top $379bn by 2024https://pharmaphorum.com/news/digital-health-market-to-top-379bn-by-2024/
